Literature DB >> 17379862

Transparency in health technology assessments.

Alan Maynard.   

Abstract

Mesh：

Year:  2007        PMID： 17379862      PMCID： PMC1832054          DOI： 10.1136/bmj.39132.363356.80

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Something rotten in the state of clinical and economic evaluations?

Authors:  N Freemantle; A Maynard
Journal:  Health Econ       Date:  1994 Mar-Apr       Impact factor: 3.046

2.  What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews.

Authors:  Trevor A Sheldon; Nicky Cullum; Diane Dawson; Annette Lankshear; Karin Lowson; Ian Watt; Peter West; Dianne Wright; John Wright
Journal:  BMJ       Date:  2004-10-30

Review 3.  From optimism to disillusion about commitment to transparency in the medico-industrial complex.

Authors:  Iain Chalmers
Journal:  J R Soc Med       Date:  2006-07       Impact factor: 18.000

4.  Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy.

Authors:  Thomas Faunce; Evan Doran; David Henry; Peter Drahos; Andrew Searles; Brita Pekarsky; Warwick Neville
Journal:  Global Health       Date:  2005-10-06       Impact factor: 4.185
  4 in total
  3 in total

1.  Construction and assumptions of models should be explicit.

Authors:  Tom Fahey
Journal:  BMJ       Date:  2007-04-21

2.  Let's open whole process of cost effective modelling.

Authors:  Jack Dowie
Journal:  BMJ       Date:  2007-04-07

3.  Community occupational therapy for older patients with dementia and their care givers: cost effectiveness study.

Authors:  Maud J L Graff; Eddy M M Adang; Myrra J M Vernooij-Dassen; Joost Dekker; L Jönsson; Marjolein Thijssen; Willibrord H L Hoefnagels; Marcel G M Olde Rikkert
Journal:  BMJ       Date:  2008-01-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.